Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Amortization - Intangibles (2019 - 2024)

Akebia Therapeutics (AKBA) has disclosed Amortization - Intangibles for 6 consecutive years, with $9.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Amortization - Intangibles changed 0.0% to $9.0 million in Q4 2024 year-over-year; TTM through Sep 2025 was $9.0 million, a 75.0% decrease, with the full-year FY2024 number at $36.0 million, changed 0.0% from a year prior.
  • Amortization - Intangibles was $9.0 million for Q4 2024 at Akebia Therapeutics, roughly flat from $9.0 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $9.1 million in Q2 2020 to a low of $6.1 million in Q3 2020.
  • A 5-year average of $8.8 million and a median of $9.0 million in 2021 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: plummeted 32.91% in 2020, then skyrocketed 47.58% in 2021.
  • Akebia Therapeutics' Amortization - Intangibles stood at $8.3 million in 2020, then increased by 8.42% to $9.0 million in 2021, then changed by 0.0% to $9.0 million in 2022, then changed by 0.0% to $9.0 million in 2023, then changed by 0.0% to $9.0 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Amortization - Intangibles are $9.0 million (Q4 2024), $9.0 million (Q3 2024), and $9.0 million (Q2 2024).